Page 2,826«..1020..2,8252,8262,8272,828..2,8402,850..»

Florida suspends doctor accused of illegal stem cell therapy

Posted: March 9, 2012 at 2:49 am

By David Fitzpatrick and Drew Griffin, Special Investigations Unit

updated 9:23 PM EST, Thu March 8, 2012

Dr. Zannos Grekos, seen here in 2009, could have his license suspended.

STORY HIGHLIGHTS

(CNN) -- A Florida cardiologist could have his medical license revoked by state authorities who have accused him of performing illegal stem cell therapy on a patient who died during the procedure.

Florida's Department of Health ordered the emergency suspension of Zannos Grekos' medical license Wednesday, accusing the Bonita Springs doctor of violating an emergency order against using stem cell treatments in Florida and causing the death of an unidentified elderly patient. Grekos can appeal the order.

According to the license suspension order, Grekos performed a stem cell treatment this month on the patient, who was suffering from pulmonary hypertension and pulmonary fibrosis. Both diseases restrict blood flow to the heart.

"During said stem cell treatment, patient R.P. suffered a cardiac arrest and died," the suspension order said.

CNN first investigated Grekos' activities in 2009, when he said he was using stem cell therapy for a company called Regenocyte Therapeutic. His profile, listed on the company's website, describes Grekos as having "extensive experience in the field of stem cell therapy" and says he "was recently appointed to the Science Advisory Board of the United States' Repair Stem Cell Institute."

At the time of CNN's interview, Grekos said he extracted stem cells from patients and then sent the blood to Israel for laboratory processing. That processing, he said, resulted in "regenocytes," which he said would help heal crippling diseases, mostly associated with lung problems.

Read more from the original source:
Florida suspends doctor accused of illegal stem cell therapy

Posted in Stem Cell Therapy | Comments Off on Florida suspends doctor accused of illegal stem cell therapy

BE THE CHANGE: Stem cells are Pamela’s last hope – can you help?

Posted: March 8, 2012 at 7:06 pm

Pamela Bousejean has Hodgkin's Lymphoma and needs a stem cell transplant. Picture: Alison Wynd Source: News Limited

PAMELA Bou Sejean is fighting for her life.

After 16 months battling an aggressive form of Hodgkin's Lymphoma, the 26-year-old has turned to Facebook in a last ditch bid to find the stem cell donor to keep her alive.

TheVictorian woman in Belmont does not match with any registered bone marrow donor in the world so is now pleading for the public to come forward to be blood tested for a possible match.

"I don't know how much time I have, I get too afraid to ask," Ms Bou Sejean told the Geelong Advertiser.

"I want to focus on what we're doing now.

"The waiting process is hard."

With her life in the balance, Ms Bou Sejean's brother Matt a week ago set up the Facebook page How You Can Help Cure Pamela.

There, Facebook users are told about her fight and how to be blood tested for a possible stem cell match.

Mr Bou Sejean who, like the rest of the family, does not match with his sister said "the cure for Pamela is in the body of hundreds of people out there."

More here:
BE THE CHANGE: Stem cells are Pamela's last hope - can you help?

Posted in Stem Cells | Comments Off on BE THE CHANGE: Stem cells are Pamela’s last hope – can you help?

Fly Research Gives Insight Into Human Stem Cell Development

Posted: March 8, 2012 at 7:06 pm

Newswise CHICAGO, IL March 8, 2012 Stem cells provide a recurring topic among the scientific presentations at the Genetics Society of Americas 53rd Annual Drosophila Research Conference, March 7-11 at the Sheraton Chicago Hotel & Towers. Specifically, researchers are trying to determine how, within organs, cells specialize while stem cells maintain tissues and enable them to repair damage and respond to stress or aging. Four talks, one on Thursday morning and three on Sunday morning, present variations on this theme.

For a fertilized egg to give rise to an organism made up of billions or trillions of cells, a precise program of cell divisions must unfold. Some divisions are asymmetric: one of the two daughter cells specializes, yet the other retains the ability to divide. Chris Q. Doe, Ph.D., professor of biology at the University of Oregon, compares this asymmetric cell division to splitting a sundae so that only one half gets the cherry. The cherries in cells are the proteins and RNA molecules that make the two cells that descend from one cell different from each other. This collecting of different molecules in different regions of the initial cell before it divides is termed "cell polarity."

Dr. Doe and his team are tracing the cell divisions that form a flys nervous system. Producing the right cells at the right time is essential for normal development, yet its not well understood how an embryonic precursor cell or stem cell generates a characteristic sequence of different cell types, he says. Dr. Doe and his team traced the cell lineages of 30 neuroblasts (stem cell-like neural precursors), each cell division generating a daughter cell bound for specialization as well as a self-renewing neuroblast. The dance of development is a matter of balance. Self-renew too much, and a tumor results; not enough, and the brain shrinks.

Tracing a cell lineage is a little like sketching a family tree of cousins who share a great-grandparent except that the great-grandparent (the neuroblast) continually produces more cousins. The offspring will change due to the different environments they are born into, says Dr. Doe.

Julie A. Brill, Ph.D., a principal investigator at The Hospital for Sick Children (SickKids) in Toronto, investigates cell polarity in sperm cells. These highly specialized elongated cells begin as more spherical precursor cells. Groups of developing sperm elongate, align, condense their DNA into tight packages, expose enzyme-containing bumps on their tips that will burrow through an eggs outer layers, form moving tails, then detach and swim away.

The Brill lab studies a membrane lipid called PIP2 (phosphatidylinositol 4,5-bisphosphate) that establishes polarity in developing male germ cells in Drosophila. Reducing levels of PIP2 leads to defects in cell polarity and failure to form mature, motile sperm, Dr. Brill says. These experiments show that localization of the enzyme responsible for PIP2 production in the growing end of elongating sperm tails likely sets up cell polarity. Since loss of this polarity is implicated in the origin and spread of cancer, defects in the regulation of PIP2 distribution may contribute to human cancer progression, she adds.

Stephen DiNardo, Ph.D., professor of cell and developmental biology at the Institute for Regenerative Medicine at the University of Pennsylvania, is investigating how different varieties of stem cells in the developing fly testis give rise to germ cells and epithelial cells that ensheathe the germ cells, as well as being able to self-renew. For each of these roles, stem cells are guided by their environment, known as their niche.

In the fly testis, we know not only the locations of the two types of stem cells whose actions maintain fertility, but of neighboring cells. We study how these niche cells are first specified during development, how they assemble, and what signals they use. Elements of what we and others learn about this niche may well apply to more complex niches in our tissues, Dr. DiNardo explains.

Denise J. Montell, Ph.D., professor of biological chemistry at Johns Hopkins University, will report on the female counterpart to the testis, the fly ovary. She and her co-workers use live imaging and fluorescent biomarkers to observe how the contractile proteins actin and myosin assemble, disassemble, and interact, elongating tissues in ways that construct the egg chamber. These approaches are particularly valuable for observing the response of the developing ovary to environmental changes. Starvation, for example, slows the rate of stem cell division and induces some egg chambers to undergo apoptosis (die) while others arrest until conditions improve, she says.

Her group has discovered that, surprisingly, following starvation and re-feeding, some of the cells that got far along the cell death pathway actually reversed that process and survived. The group has documented this reversal of apoptosis in a variety of mammalian cell types including primary heart cells. These observations have many intriguing implications. This may represent a previously unrecognized mechanism that saves cells that are difficult to replace, and therefore, may have implications for treating degenerative diseases.

Read the original post:
Fly Research Gives Insight Into Human Stem Cell Development

Posted in Stem Cells | Comments Off on Fly Research Gives Insight Into Human Stem Cell Development

Neuralstem Shows Solid Progress in Spinal Cord Neural Stem Cell Trial for ALS

Posted: March 8, 2012 at 7:06 pm

MissionIR would like to highlight Neuralstem, Inc. (NYSE AMEX: CUR). The company's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In addition to ALS, Neuralstem is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease.

In the company's news yesterday,

Neuralstem reported dosing of the fourteenth patient in its ongoing Phase I clinical trialing of the companys spinal cord neural stem cells in ALS (amyotrophic lateral sclerosis or Lou Gehrigs disease), marking the second patient to receive cells in the cervical (upper back) region of the spine and the trials first female patient. This is the first FDA-approved neural stem cell trial for the treatment of ALS.

This treatment is designed to help remediate breathing function loss associated with progressive ALS, and the transplantation of stem cells observed in the trial will be keenly watched for safety/efficacy of spinal cord neural stem cells, as well as the intraspinal transplantation method. The first twelve patients received lumbar (lower back) transplants and the trial has now been underway since January of 2010.

Having begun with non-ambulatory patients and progressing to patients able to walk, this trial has now entered into the final six patients, all of whom will receive cervical transplants, with trial conclusion projected for six months after the final surgery is complete. The proprietary CUR spinal cord delivery platform with floating cannula has helped tremendously in making this dream a possibility and represents a true breakthrough in the field, making the first ever intraspinal injections feasible.

Chairman and CSO of CUR, Karl Johe, PhD., was proud to be breaking new ground with this latest cohort of patients, as it represents a major milestone for the trial, with direct implantation of cells into the gray matter of the spinal cord in the cervical region. Dr. Johe was especially proud of the potential these successful surgeries represent for the numerous patients who suffer from significant quality of life impairment due to ALS. With the 14th successful transplant notched into their belts, CUR is confident that the demonstration of safety in this novel procedure is going quite well.

This is a huge coup for CUR which is also making significant advancements towards developing a robust cell therapy platform capable of addressing a wide range of major central nervous system conditions, ranging from spinal cord injuries and chronic stroke, to ischemic spastic paraplegia and other crippling conditions. The company has an IND submitted to FDA for Phase I safety trials in chronic spinal cord injury.

The company is also well-positioned to service systematic screening needs in the large chemical library space. With proprietary screening technology and the ability to generate appropriate human neural stem cell lines, CUR is ready to leverage discovered/patented compounds that help to stimulate brain activity and neuron regeneration. The potential exists to even reverse debilitating CNS conditions.

The company has also received FDA clearance to conduct a Phase Ib safety trial for their first small molecule compound, NSI-189, for treatment of MDD (major depressive disorder); technology that could easily pan out into schizophrenia, bipolar disorder, and Alzheimers offerings.

About MissionIR

See the original post here:
Neuralstem Shows Solid Progress in Spinal Cord Neural Stem Cell Trial for ALS

Posted in Stem Cells | Comments Off on Neuralstem Shows Solid Progress in Spinal Cord Neural Stem Cell Trial for ALS

Stem cells beat kidney rejection

Posted: March 8, 2012 at 7:06 pm

8 March 2012 Last updated at 04:20 ET

An injection of stem cells given alongside a kidney transplant could remove the need for a lifetime of drugs to suppress the immune system, say scientists.

Early tests of the technique at US hospitals were successful in a small number of patients.

The journal Science Translational Medicine reports how the majority no longer need anti-rejection medication.

Researchers said it could have a "major impact" on transplant science.

One of the key problems associated with organ transplantation is the risk that the body will "recognise" the new organ as a foreign invader and attack it.

To prevent this, patients take powerful drugs to suppress their immune systems, and will have to do this for life.

The drugs come at a price, preventing organ rejection but increasing the risk of high blood pressure, diabetes and serious infection.

The study, carried out at the University of Louisville and the Northwestern Memorial Hospital in Chicago, involved eight patients.

Their transplant came from a live donor, who also underwent a procedure to draw stem cells, the building blocks of their immune system, from the blood.

Go here to read the rest:
Stem cells beat kidney rejection

Posted in Stem Cells | Comments Off on Stem cells beat kidney rejection

Fly research gives insight into human stem cell development and cancer

Posted: March 8, 2012 at 7:04 pm

Public release date: 8-Mar-2012 [ | E-mail | Share ]

Contact: Phyllis Edelman pedelman@genetics-gsa.org 301-351-0896 Genetics Society of America

CHICAGO, IL March 8, 2012 Stem cells provide a recurring topic among the scientific presentations at the Genetics Society of America's 53rd Annual Drosophila Research Conference, March 7-11 at the Sheraton Chicago Hotel & Towers. Specifically, researchers are trying to determine how, within organs, cells specialize while stem cells maintain tissues and enable them to repair damage and respond to stress or aging. Four talks, one on Thursday morning and three on Sunday morning, present variations on this theme.

For a fertilized egg to give rise to an organism made up of billions or trillions of cells, a precise program of cell divisions must unfold. Some divisions are "asymmetric": one of the two daughter cells specializes, yet the other retains the ability to divide. Chris Q. Doe, Ph.D., professor of biology at the University of Oregon, compares this asymmetric cell division to splitting a sundae so that only one half gets the cherry. The "cherries" in cells are the proteins and RNA molecules that make the two cells that descend from one cell different from each other. This collecting of different molecules in different regions of the initial cell before it divides is termed "cell polarity."

Dr. Doe and his team are tracing the cell divisions that form a fly's nervous system. "Producing the right cells at the right time is essential for normal development, yet it's not well understood how an embryonic precursor cell or stem cell generates a characteristic sequence of different cell types," he says. Dr. Doe and his team traced the cell lineages of 30 neuroblasts (stem cell-like neural precursors), each cell division generating a daughter cell bound for specialization as well as a self-renewing neuroblast. The dance of development is a matter of balance. Self-renew too much, and a tumor results; not enough, and the brain shrinks.

Tracing a cell lineage is a little like sketching a family tree of cousins who share a great-grandparent except that the great-grandparent (the neuroblast) continually produces more cousins. "The offspring will change due to the different environments they are born into," says Dr. Doe.

Julie A. Brill, Ph.D., a principal investigator at The Hospital for Sick Children (SickKids) in Toronto, investigates cell polarity in sperm cells. These highly specialized elongated cells begin as more spherical precursor cells. Groups of developing sperm elongate, align, condense their DNA into tight packages, expose enzyme-containing bumps on their tips that will burrow through an egg's outer layers, form moving tails, then detach and swim away.

The Brill lab studies a membrane lipid called PIP2 (phosphatidylinositol 4,5-bisphosphate) that establishes polarity in developing male germ cells in Drosophila. "Reducing levels of PIP2 leads to defects in cell polarity and failure to form mature, motile sperm," Dr. Brill says. These experiments show that localization of the enzyme responsible for PIP2 production in the growing end of elongating sperm tails likely sets up cell polarity. Since loss of this polarity is implicated in the origin and spread of cancer, defects in the regulation of PIP2 distribution may contribute to human cancer progression, she adds.

Stephen DiNardo, Ph.D., professor of cell and developmental biology at the Institute for Regenerative Medicine at the University of Pennsylvania, is investigating how different varieties of stem cells in the developing fly testis give rise to germ cells and epithelial cells that ensheathe the germ cells, as well as being able to self-renew. For each of these roles, stem cells are guided by their environment, known as their "niche."

In the fly testis, we know not only the locations of the two types of stem cells whose actions maintain fertility, but of neighboring cells. "We study how these niche cells are first specified during development, how they assemble, and what signals they use. Elements of what we and others learn about this niche may well apply to more complex niches in our tissues," Dr. DiNardo explains.

Here is the original post:
Fly research gives insight into human stem cell development and cancer

Posted in Cell Medicine | Comments Off on Fly research gives insight into human stem cell development and cancer

Nuvilex Points Toward Cell Encapsulation Technology Future to Expand Stem Cell Use for Late Stage Cancer Treatments

Posted: March 8, 2012 at 7:04 pm

SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today discussed the potential use of the companys cell encapsulation technology with modified stem cells to treat late stage cancers.

Stem cell therapy is not new to physicians dealing with blood and bone cancers, with stem cell transplants being an important treatment for growing new bone marrow since the 1970s. Recent studies have indicated the potential for using stem cells across a much broader range of cancers is becoming a reality, mostly a result of advances in cell and molecular biology techniques.

Traditional chemotherapy works by targeting the fast-growing cells common to cancer tumors. Unfortunately, chemotherapeutics dont differentiate between healthy and cancerous cells. Patients suffering from metastatic cancers, where tumors have spread to multiple areas of the body, often have substantial difficulties with the chemotherapy needed to treat their disease.

In one case, researchers at City of Hope and St. Jude Children's Research Hospital may have found a way to treat cancers that have spread throughout the body more effectively. They used genetically modified stem cells to activate chemotherapeutic drugs at the tumor sites, so that normal tissue surrounding the tumor and throughout the body remain relatively unharmed. The stem cells were designed to produce a specific enzyme that converts the nontoxic prodrug into the chemotherapeutic agent. This method also targets the brain tumor treatment to remain localized within the brain, similar to the pancreatic cancer clinical trial carried out by SG Austria, providing for high dosage chemotherapy without affecting surrounding tissues and avoiding the severe side effects normally associated with cancer therapy.

Nuvilex believes that incorporating Cell-in-a-Box encapsulation with this type of genetically modified stem cell, along with the proprietary cancer treatment being acquired, could significantly aid and improve patient outcomes.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, We are hopeful for the day when late stage cancers can be routinely and safely treated using genetically modified cells like those used in the pancreatic cancer trial, increasing the ability of clinicians to avoid inducing side effects that typically accompany aggressive chemotherapy and/or radiation. Our cell encapsulation technology will enable practitioners to target tumors while preserving the health of the surrounding tissues. We continue to look for leading stem cell and oncology researchers to partner with us as we bring this technology to market.

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Through our effort, all aspects of our corporate activities alone, and especially in concert with SG Austria, are rapidly moving toward completion, including closing our agreement. One of our planned offerings will include cancer treatments using the companys industry-leading live-cell encapsulation technology.

Safe Harbor Statement

Visit link:
Nuvilex Points Toward Cell Encapsulation Technology Future to Expand Stem Cell Use for Late Stage Cancer Treatments

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Nuvilex Points Toward Cell Encapsulation Technology Future to Expand Stem Cell Use for Late Stage Cancer Treatments

Florida suspends doctor accused of illegal stem cell therapy

Posted: March 8, 2012 at 7:04 pm

By David Fitzpatrick and Drew Griffin, Special Investigations Unit

updated 1:34 PM EST, Thu March 8, 2012

Dr. Zannos Grekos, seen here in 2009, could have his license suspended.

STORY HIGHLIGHTS

(CNN) -- A Florida cardiologist could have his medical license revoked by state authorities who have accused him of performing illegal stem cell therapy treatment on an elderly patient who died during the procedure.

Florida's Department of Health ordered the emergency suspension of Dr. Zannos Grekos' medical license Wednesday, accusing the Bonita Springs doctor of violating an emergency order against using stem cell treatments in Florida and allegedly causing the death of an unnamed elderly patient. Grekos can appeal the order.

According to the license suspension order, Grekos performed a stem cell treatment earlier this month on the patient, who was suffering from pulmonary hypertension and pulmonary fibrosis. Both diseases restrict blood flow to the heart.

"During said stem cell treatment, patient R.P. suffered a cardiac arrest and died," the suspension order said.

CNN first investigated Grekos's activities in 2009 and, at that time, he said he was using stem cell therapy for a company he called Regenocyte Therapeutic. His profile, listed on the company's website, describes Grekos as having "extensive experience in the field of stem cell therapy" and says he "was recently appointed to the Science Advisory Board of the United States' Repair Stem Cell Institute."

At the time of CNN's interview, Grekos said he extracted stem cells from patients and then sent the blood to Israel for laboratory processing. That processing, he said, resulted in "regenocytes," which he claimed would help heal crippling diseases, mostly associated with lung problems.

Originally posted here:
Florida suspends doctor accused of illegal stem cell therapy

Posted in Stem Cell Therapy | Comments Off on Florida suspends doctor accused of illegal stem cell therapy

UofL Professor’s study: Stem cells eliminate need for anti-rejection drugs

Posted: March 8, 2012 at 7:46 am

by Maggie Ruper

WHAS11.com

Posted on March 7, 2012 at 11:50 PM

Updated today at 12:01 AM

LOUISVILLE, Ky. (WHAS11) -- New research published Wed. in the journal Science Translation Medicine, shows organ transplant recipients may not require anti-rejection medication after surgery.

The study, authored by University of Louisville professor Suzanne Ildstad, M.D., suggests bone marrow stem cells are able to trick the recipients immune system into thinking the donated organ is part of the patients natural self. It therefore eliminates the need for patients to take dozens of daily anti-rejection drugs.

Normally, if I have to transplant a kidney into a patient they have to take immunosuppression drugs for their lifetime and that's about 15 to 25 pills a day, said Ildstad.

Louisville native and father of four, Rob Waddell underwent the procedure in 2009 at Northwestern Memorial Hospital. He suffered from Polycystic Kidney Disease since he was 11 years old. His new kidney and the stem cells were donated to him by his next door neighbor.

It was a match and the rest is history. He's what I call my guardian angel," said Wadell.

The results were considered important because the technique worked for patients who did not have well-matched or related donors.

Go here to read the rest:
UofL Professor’s study: Stem cells eliminate need for anti-rejection drugs

Posted in Stem Cells | Comments Off on UofL Professor’s study: Stem cells eliminate need for anti-rejection drugs

Transplant without lifetime of drugs?

Posted: March 8, 2012 at 7:44 am

Lindsay Porter's kidneys weighed 16 pounds before her transplant.

STORY HIGHLIGHTS

(CNN) -- By the time Lindsay Porter had her kidneys removed two years ago, they were bulging -- covered in cysts -- and together weighed 16 pounds.

Her abdominal area was so distended, "I looked nine months pregnant, and people regularly asked when I was due," Porter said.

As she prepared for a transplant to address her polycystic kidney disease, Porter, 47, had mixed feelings -- relief to have found a donor, tinged with resignation. She was looking forward to both a new kidney, and a lifetime on immune system-suppressing drugs.

"You get this brand new shiny kidney, and then they give you drugs that eventually destroy it," said Porter.

But that scenario may eventually change, if results of a new pilot study are replicated in a larger group of patients. The study, published Wednesday in the journal Science Translational Medicine, describes eight kidney transplant patients, including Porter, who received a stem cell therapy that allowed donor and recipient immune cells to coexist in the same body.

The effect, in a handful of those patients, was to trick the recipient's immune system into recognizing the donated kidney as its own.

When it works, patients become a sort of medical rarity called a chimera.

"Chimerism is a condition wherein two different genetic cell populations are present in the body, and both cell types are tolerated," said Dr. Anthony Atala, director of the Institute for Regenerative Medicine at Wake Forest Baptist Medical Center, who was not involved in the study, via e-mail.

See more here:
Transplant without lifetime of drugs?

Posted in Stem Cell Therapy | Comments Off on Transplant without lifetime of drugs?

Page 2,826«..1020..2,8252,8262,8272,828..2,8402,850..»